Compare · A vs EYPT
A vs EYPT
Side-by-side comparison of Agilent Technologies Inc. (A) and EyePoint Inc. (EYPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and EYPT operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- A is the larger of the two at $49.04B, about 1392.6x EYPT ($35.2M).
- EYPT has been more active in the news (8 items in the past 4 weeks vs 7 for A).
- A has more recent analyst coverage (25 ratings vs 20 for EYPT).
- Company
- Agilent Technologies Inc.
- EyePoint Inc.
- Price
- -
- -
- Market cap
- $49.04B
- $35.2M
- 1M return
- -0.16%
- -
- 1Y return
- +19.60%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 20
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Latest A
- Agilent to Participate in 9th Annual Evercore Healthcare Conference
- Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
- Agilent Completes Acquisition of Proscia
- Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows
- Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
- Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research
- Deutsche Bank initiated coverage on Agilent with a new price target
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
Latest EYPT
- Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.
- SEC Form 10-Q filed by EyePoint Inc.
- EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
- EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
- EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.
- SEC Form SCHEDULE 13G filed by EyePoint Inc.
- EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
- EyePoint downgraded by Analyst